Silver Lake Acquires Grupo BC from L-GAM
Grupo BC, the leading mortgage management, legal and digital services provider to the financial sector in Iberia and Latin America, today announced that Silver Lake, a leading global technology investment firm, together with Grupo BC’s founding shareholders and management team, will acquire 100% of the company from majority holders L-GAM in order to foster the next phase of Grupo BC’s growth and value creation.
Santiago Bellver, Chairman of Grupo BC, and Xavier Costa, CEO of Grupo BC, said: “We are grateful to L-GAM for the support and collaboration over the six years of their investment in Grupo BC, and delighted about the new partnership with Silver Lake, a leading global technology investor which has placed their trust in us and with whom we will be able to strengthen our organic growth thanks to their technological expertise and through selective acquisitions. We will shortly communicate the objectives of our strategic plan and the composition of the new Board of Directors.”
Christian Lucas, Co-Head of Silver Lake EMEA, said: “Grupo BC is an outstanding company with a unique value proposition as a scaled and tech-enabled provider of mission-critical services and software to financial institutions across Iberia and Latin America. We are impressed by the way Santiago, Xavier and the rest of the team have developed and continuously digitalized the Grupo BC platform over the years, building it into the partner of choice for clients across its ecosystem. Investing in impactful, leading and technology-enabled business models is at the core of Silver Lake’s DNA, and we feel privileged to partner with management as Grupo BC enters a new phase of organic and inorganic growth.”
Felipe Merry del Val and Tito Soso, Partners at L-GAM, added: “Our journey with Grupo BC has been a remarkable story of transformation, several fold growth and success, and importantly a hugely rewarding partnership with a world-class management team led by Chairman Santiago Bellver and CEO Xavier Costa, whom we thank for the tremendous effort and achievement. We wish Grupo BC continued success in their future exciting endeavours.”
Founded in 1974 and headquartered in Madrid, Grupo BC is the leading tech-enabled processing platform, software and services provider for mortgage management, online mortgage brokerage, legal solutions (claims processing and loan management), and digital solutions to the financial sector in Spain, Portugal, Mexico, Brazil, Colombia, Chile and Peru. Grupo BC is a market leader across its key focus areas with more than 500,000 mortgage files processed per year and 5,300 employees. For more information, please visit https://www.grupobc.com.
Silver Lake’s investment is intended to further product development in order to strengthen and expand Grupo BC’s solution range as well as to continue its track-record of pioneering digital innovation, consistent with management’s clear focus on building out Grupo BC’s software and data analytics capabilities to enhance its client-centric solutions and drive continued organic and inorganic growth.
The transaction is anticipated to close in November 2021. Further terms of the investment are not being disclosed. Socios Financieros and Canson Capital Partners served as the financial advisors to Grupo BC and its shareholders. dwf-RCD served as the legal advisor to Grupo BC and its shareholders. Paul, Weiss, Rifkind, Wharton & Garrison LLP and Uría Menéndez served as the legal advisor to Silver Lake.
About Silver Lake
Silver Lake is a global technology investment firm, with more than $88 billion in combined assets under management and committed capital and a team of professionals based in North America, Europe and Asia. Silver Lake's portfolio companies collectively generate more than $221 billion of revenue annually and employ more than 526,000 people globally. For more information about Silver Lake and its portfolio, please visit http://www.silverlake.com.
About L-GAM
L-GAM is an international investment company founded in 2013 by its professionals in partnership with the Princely House of Liechtenstein and other major European, Asian and American families. Its unique and differentiated business model is based on a long term, industrial like investment focus in partnership with highly reputed SMEs throughout Europe. For more information about L-GAM, please visit http://www.l-gam.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005511/en/
Contact information
Media
For Silver Lake:
Spain: Paula Bonet, paula.bonet@edelman.com, +34 629 814 440
International: Jess Gill, Edelman Smithfield, silverlakemedia@edelman.com, +44 (0)7980 684 247
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom